Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.61 EUR | -1.14% | -3.33% | -3.33% |
May. 09 | Uniphar says trading in line, reports good start to 2024 | AN |
May. 09 | Uniphar Logs Organic Gross Profit Growth in FY23, Affirms FY24 Guidance | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The stock, which is currently worth 2024 to 0.35 times its sales, is clearly overvalued in comparison with peers.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.33% | 773M | C+ | ||
+23.03% | 74.04B | C+ | ||
-1.52% | 24.18B | C+ | ||
+3.67% | 8.46B | C | ||
+8.55% | 8.34B | B | ||
-23.71% | 7.64B | B- | ||
+15.20% | 5.33B | B- | ||
-6.90% | 3.92B | B- | ||
+2.68% | 4.12B | B | ||
+5.56% | 3.89B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UPR Stock
- Ratings Uniphar plc